Literature DB >> 11774094

The United States Food and Drug Administration and the end of antibiotics.

David M Shlaes, Robert C Moellering.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11774094     DOI： 10.1086/338976

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  17 in total

1.  The FDA reboot of antibiotic development.

Authors:  David M Shlaes; Dan Sahm; Carol Opiela; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

2.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 3.  Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 5.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

7.  Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial.

Authors:  Isabelle Cochereau; Pablo Goldschmidt; André Goepogui; Tayyab Afghani; Laurent Delval; Pascale Pouliquen; Tristan Bourcier; Pierre-Yves Robert
Journal:  Br J Ophthalmol       Date:  2006-09-27       Impact factor: 4.638

8.  Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good.

Authors:  B Spellberg; K A Marr; E P Brass
Journal:  Clin Pharmacol Ther       Date:  2016-10-14       Impact factor: 6.875

Review 9.  Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Authors:  Brad Spellberg; George H Talbot; Helen W Boucher; John S Bradley; David Gilbert; W Michael Scheld; John Edwards; John G Bartlett
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

10.  Synergistic interactions of methanolic extract of Acacia mearnsii De Wild. with antibiotics against bacteria of clinical relevance.

Authors:  Olufunmiso O Olajuyigbe; Anthony J Afolayan
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.